On February 13, 2025, GE HealthCare Technologies Inc (GEHC, Financial) released its 8-K filing detailing the financial results for the fourth quarter and full year of 2024. The company, a leader in medical technology with significant market share in imaging and ultrasound equipment, reported notable achievements in revenue growth and margin expansion.
GE HealthCare Technologies Inc (GEHC, Financial) operates across four major segments: imaging, ultrasound, patient care solutions, and pharmaceutical diagnostics. The company's revenue is geographically diverse, with significant contributions from the United States, EMEA, China, and other regions. Approximately half of its revenue is recurring, stemming from services, pharmaceutical diagnostics, and digital solutions.
In the fourth quarter of 2024, GE HealthCare reported a 2% year-over-year increase in revenue, reaching $5.3 billion. This growth was driven by strong demand in Advanced Visualization Solutions and Pharmaceutical Diagnostics, particularly in the U.S. market. The company's net income margin improved significantly to 13.5%, up from 7.7% in the previous year, highlighting effective cost management and operational efficiency.
Despite these positive results, the company faced challenges such as a decline in cash flow from operating activities, which decreased to $913 million from $1.1 billion in the prior year. This reduction in cash flow could pose potential liquidity challenges if not addressed.
GE HealthCare's financial achievements are noteworthy, particularly in the context of the healthcare industry. The company's adjusted EBIT margin increased to 18.7% from 16.1%, reflecting improved productivity and volume. Diluted EPS for the quarter was $1.57, surpassing the analyst estimate of $1.31. Adjusted EPS was $1.45, also exceeding expectations.
The income statement revealed a net income attributable to GE HealthCare of $720 million, a substantial increase from $403 million in the prior year. The balance sheet showed total assets of $33.1 billion, with cash and cash equivalents rising to $2.9 billion. The company's free cash flow was $811 million, down from $956 million, indicating a need for careful cash management.
GE HealthCare President and CEO Peter Arduini stated, “We were pleased with the strong momentum in orders, backlog and book-to-bill that we saw in the fourth quarter. We also continued to deliver revenue growth driven by demand in our Advanced Visualization Solutions and Pharmaceutical Diagnostics businesses, with overall strength in the U.S., and robust margin expansion and earnings growth.”
| Metric | Q4 2024 | Q4 2023 | YoY Change |
|---|---|---|---|
| Revenue | $5.3 billion | $5.2 billion | 2% |
| Net Income | $720 million | $403 million | 78.7% |
| Diluted EPS | $1.57 | $0.88 | 78.4% |
| Free Cash Flow | $811 million | $956 million | -15.2% |
GE HealthCare's performance in Q4 2024 demonstrates its ability to capitalize on market opportunities and drive growth through innovation and strategic initiatives. The company's focus on precision care and new product introductions has contributed to its success. However, the decline in cash flow and potential market softness in China remain areas to monitor closely.
Looking ahead, GE HealthCare has introduced its 2025 guidance, projecting organic revenue growth of 2% to 3% and adjusted EPS growth of 3% to 6%. The company's strategic partnerships and investments in AI-enabled diagnostic equipment are expected to support its growth trajectory.
Explore the complete 8-K earnings release (here) from GE HealthCare Technologies Inc for further details.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.